Research Article
Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study

Assaf Moore,1,2 Idit Peretz,1 Lilach Yosef,1 Daniel A. Goldstein,1,2 Hadar Goldvaser,1,2 Suzanna Horn,2,3 Yonatan Edel,2,4,5 and Alona Zer1,2

1Institute of Oncology, Davidoff Center, Rabin Medical Center—Beilinson Hospital, Petach Tikva, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Pathology Department, Rabin Medical Center—Beilinson Hospital, Petach Tikva, Israel
4Rheumatology Unit, Rabin Medical Center—Beilinson Hospital, Petach Tikva, Israel
5Medicine C, Rabin Medical Center—Beilinson Hospital, Petach Tikva, Israel

Correspondence should be addressed to Assaf Moore; assafmoore@gmail.com

Received 22 July 2020; Revised 17 November 2020; Accepted 19 November 2020; Published 1 December 2020

Background. Kaposi sarcoma (KS) is an angioproliferative disorder, originating from endothelial cells, myofibroblasts, and monocyte-macrophage cells. Four subtypes have been identified: classical KS (CKS); endemic, described in sub-Saharan indigenous Africa; iatrogenic, associated with immunosuppression; and AIDS associated. While KS has been described globally, the disease is most frequent in Mediterranean populations and Central and Eastern Europe [1–4]. KS was found to have distinct risk and etiological factors. KS is more frequent in men and usually presents in the seventh and eight decades of life. Only 4–8% of patients present under the age of 50 years [5, 6]. KS was found to be strongly associated with human herpes virus 8 (HHV-8) infection [7]. Its incidence was found to be 20,000 times more frequent in patients with AIDS compared with the general population and 300 times more frequent compared with other immune-suppressed patient groups [8]. It is more commonly associated with HIV-1 infection than with HIV-2 infection [9]. KS was also found to be associated with anemia.

1. Background

Kaposi sarcoma (KS) is an angioproliferative disorder, originating from endothelial cells, myofibroblasts, and monocyte-macrophage cells. Four subtypes have been identified: classical KS (CKS); endemic, described in sub-Saharan indigenous Africa; iatrogenic, associated with immunosuppression; and AIDS associated. While KS has been described globally, the disease is most frequent in Mediterranean populations and Central and Eastern Europe [1–4]. KS was found to have distinct risk and etiological factors. KS is more frequent in men and usually presents in the seventh and eight decades of life. Only 4–8% of patients present under the age of 50 years [5, 6]. KS was found to be strongly associated with human herpes virus 8 (HHV-8) infection [7]. Its incidence was found to be 20,000 times more frequent in patients with AIDS compared with the general population and 300 times more frequent compared with other immune-suppressed patient groups [8]. It is more commonly associated with HIV-1 infection than with HIV-2 infection [9]. KS was also found to be associated with anemia.
Sarcoma

Student’s t-test was used for continuous data. The χ2 test was used for categorical data, and the Student’s t-test was used for continuous data.

2. Methods

2.1. Patients. The registry of the pathology department at the Rabin Medical Center was screened for all patients diagnosed with sarcomas/carcinosarcomas between 1/2012–12/2017. Patients with a diagnosis of CKS comprised one cohort, and patients diagnosed with all other sarcomas or carcinosarcomas comprised the “control” cohort. Patients’ demographics and clinicopathological characteristics were extracted from electronic hospital and community-based medical records. Patients younger than 18 years of age and patients without available clinical data were excluded from this analysis. The study was approved by the institutional ethics committees prior to any research procedures.

2.2. Statistics Analysis. Association between diagnosis of gout and CKS was calculated and adjusted for risk factors including age, sex, and medical comorbidities using a logistic regression test via MEDCALC® statistical software [20]. Associations were presented with odds ratio (OR) and 95% confidence interval (CIs). A significance level of 0.05 was used. The χ2 test was used for categorical data, and the Student’s t-test was used for continuous data.

3. Results

A total of 700 patients with a pathological diagnosis of sarcoma or carcinosarcoma were located in the registries. After exclusion of 339 cases not meeting the inclusion criteria, 361 patients were eligible for this analysis and comprised the study cohort. Of them, 61 patients were diagnosed with CKS and comprised the study group, and 300 patients with other types of sarcoma or carcinosarcoma comprised the control group.

The CKS cohort was significantly older than the general sarcoma cohort and had a larger proportion of male patients, as well as a significantly higher proportion of medical comorbidities, including hypertension, diabetes mellitus, and solid organ transplantation. There was no significant difference in oral steroid use. We found a higher incidence of gout in CKS patients, 11/61 (18%), compared with 8/300 (2.6%) with other types of sarcoma and carcinosarcoma (OR = 8.0, 95% CI 3.08–20.94, P < 0.0001), as well as a more common use of allopurinol in patients with CKS. Patient characteristics are available in Table 1.

The association between CKS and gout remained significant when adjusting for single confounding factors, such as age at diagnosis >39 years (OR 6.7, 95% CI 2.4–18.1, P < 0.0001), male sex (OR 6, 3, 95% CI 2.4–16.7, P < 0.0001), diabetes mellitus (OR 9.1, 95% CI 3.4–24.3, P < 0.0001), and oral steroid use (OR 8.2, 95% CI 3.1–21.5, P = 0.0001).

When adjusting for both age (>39 years) and male sex, the OR was 5.0 (95% CI 1.8–13.7, P < 0.0001). The association also remains significant when adjusting for multiple factors, such as age at diagnosis, sex, and hypertension (OR 5.0, 95% CI 1.8–14.0, P < 0.0001) and age at diagnosis, sex, hypertension, diabetes mellitus, and oral steroid use (OR 7.2, 95% CI 2.6–20.1, P < 0.0001).

4. Discussion

This study identified a statistically significant association between gout and CKS, as compared with a cohort of patients with non-Kaposi sarcomas and carcinosarcomas. As expected, the use of allopurinol was more prevalent among patients with CKS. While the CKS cohort had more risk factors for gout, including older age, a higher prevalence of male patients and medical comorbidities was known to be associated with gout, when adjusting for these confounders separately and in conjunction, and the significant association remained.

Two studies have previously reported on such a possible association. In one study, a higher incidence of gout was found in a cohort of classical KS compared with HHV8-positive controls, 14/142 vs. 8/123 patients, OR 1.28 (0.45–3.62) [11]. The CKS cohort had a higher prevalence of diabetes mellitus, kidney failure, and oral steroid use compared with a randomly selected sex and age-matched HHV8-seropositive cohort [11]. That study did not report on organ transplantation. In the second study, a CKS cohort was also compared with an HHV8-seropositive control cohort of the same age and sex and from the same communities. That study also reported an increased risk for KS with a history of gout (OR = 2.13, 95% CI = 0.74 to 6.15), a higher prevalence of steroid use in CKS patients, no excess kidney failure, and no cases of organ transplantation [12]. In both studies, the higher prevalence of gout in CKS patients was not statistically significant [11, 12]. The median age in these studies was similar to that of our CKS cohort; however, we found no difference in the prevalence of steroid use, and we did not account for kidney function. We selected a non-Kaposi cancer-control cohort in this study to overcome a potential causation with malignancy or paraneoplastic phenomenon. Our results are strengthened by the fact that our non-Kaposi cancer-control
cohort had a similar prevalence of gout compared with rates reported in the literature [18].

While our results are not in accordance with these previous reports, potential explanations for this association can be considered. HHV8 can establish a lifelong infection. In order to enter the latent phase, the virus modulates the host’s innate immune response [21–23]. Toll-like receptors (TLRs) are transmembrane proteins that are key components of the innate immune system’s ability to recognize invading pathogens. TLRs 2, −3, −4, −7, −8, and −9 have been recognized to be involved in the recognition of viruses [24–26]. HHV8 is known to have complex interactions with TLRs resulting in their activation. One study found that, through infection of THP-1 and CD14-positive primary human monocytes, HHV8 upregulates the TLR3 pathway and induces TLR3-specific cytokines and chemokines, including beta 1 interferon (IFN-β1) and CXCL10 (IP-10) [27]. CXCL10 is an important chemokine that can regulate immune responses through the activation and recruitment of immune cells [28, 29]. CXCL10 has been shown to be involved in the development of arthritis [30].

A gout flare is characterized by an acute inflammatory response that occurs in the synovium by urate crystal deposition or release. Neutrophil phagocytosis of crystals in the aspirated synovial fluid is the hallmark for diagnosis of gout [31]. However, many other inflammatory processes occur prior to and during neutrophil activation. Gout-related inflammation is thought to be related in part to TLR-dependent inflammatory response. One study showed that, in patients with gout, hyperuricemia causes a shift in the IL-1β/IL-1Ra balance produced by peripheral blood mononuclear cells (PBMCs) after exposure to MSU crystals and TLR (3 and 4 ligand)-mediated stimuli, and this phenomenon is likely to reinforce the enhanced state of chronic inflammation [32]. In another study, monocytes from healthy volunteers were primed with uric acid, leading to increased activity in mammalian target of rapamycin (mTOR) signaling. This led to lower autophagic activity in cells exposed to uric acid compared with control conditions and diminished reactive oxygen species production [33].

TLRs and CXCL10 may provide a partial explanation to the potential association between CKS and gout, as the first was shown to upregulate an important TLR in gout, as well as an important chemokine to the development of arthritis. In fact, drugs targeting CXCL10 may be a new therapeutic approach for acute gouty arthritis [30, 34].

Furthermore, a study demonstrated how HHV8 infection involved with KS interacts with procaspase-1 to form functional inflammasomes [35]. The inflammasome acts as a sensor for various types of molecules in the cytoplasm, including RNA viruses, and is responsible for the activation of inflammatory responses of the innate immune system [36]. In gout, the IL-1-dependent innate inflammatory phenotype is now known to rely on the formation of the macromolecular NLRP3 inflammasome complex in response to the MSU [37]. This common feature of inflammasome activation may also contribute to a common pathophysiology.

The main limitations of this study relate to its retrospective design that is generally associated with methodological biases, especially selection bias, and difficulties in interpreting results. The study strengths include consecutive patient enrolment and being a relatively large size single institution cohort. Another strength is the availability of community-based patient follow-up on joint databases, which allows for better patient follow-up and documentation of comorbidities.

5. Conclusions

We have demonstrated a statistically significant association between CKS and gout. As risk factors for gout were accounted for, this association may be explained by HHV8 immune-related effects. This should be further explored in vitro and in population-based studies.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

Assaf Moore declares honoraria from Merck, Roche. Idit Perez, Lilach Yosef, Daniel A. Goldstein, Suzanna Horn, and Yonatan Edel declare no conflicts of interest to disclose. Hadar Goldvaser declares honoraria from Novartis, Roche, Pfizer, Oncotest. Alona Zer declares advisory role from Astra

Table 1: Patients’ characteristics, n = 366.

| Factor                        | CKS cohort, n = 61 | General sarcoma cohort, n = 300 | P value                         | OR   |
|------------------------------|-------------------|--------------------------------|--------------------------------|------|
| Median age, years (range)    | 78 (39–94)        | 68 years (39–99)                | <0.0001 (95% CI 4.97–12.20)    | —    |
| Male sex, n (%)              | 46 (75.4%)        | 155 (51.7%)                    | <0.0007 (95% CI 1.53–5.36)     | 2.9, 95% CI 1.96–3.13 |
| Hypertension, n (%)          | 42 (68.8%)        | 168 (56%)                      | 0.06 (95% CI 0.86–2.76)        | 1.7, 95% CI 0.96–3.13 |
| Diabetes mellitus, n (%)     | 24 (39.3%)        | 88 (29.3%)                     | 0.12 (95% CI 0.89, 1.74)       | 0.89, 95% CI 0.45–1.74 |
| Oral steroid use, n (%)      | 13 (21.3%)        | 70 (23.3%)                     | 0.73 (95% CI 3.08–20.94)       | 8.0, 95% CI 3.25–14.34 |
| Gout, n (%)                  | 11 (18%)          | 8 (2.6%)                       | <0.00001 (95% CI 3.08–20.94)   | 5.7, 95% CI 2.25–14.34 |
| Regular allopurinol use, n (%)| 10 (16.4%)        | 10 (3.3%)                      | <0.0001 (95% CI 3.08–20.94)    | —    |

CKS, classical Kaposi sarcoma; n, number; OR, odds ratio.
Zeneca, Merck, Roche; honoraria from Astra Zeneca, Bristol Myers Squibb, Merck, Roche; and research funding from Bristol Myers Squibb.

Authors’ Contributions
Assaf Moore and Idit Perez contributed equally to this work.

References
[1] E. Cesarman, B. Damania, S. E. Krown, J. Martin, M. Bower, and D. Whitby, “Kaposi sarcoma,” Nature Reviews Disease Primers, vol. 5, no. 1, p. 9, 2019.

[2] P. Cattani, F. Cerimele, D. Porta et al., “Age-specific sero-prevalence of human herpesvirus 8 in mediterranean regions,” Clinical Microbiology and Infection, vol. 9, no. 4, pp. 274–279, 2003.

[3] A. Angeloni, L. Heston, S. Uccini et al., “High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi’s sarcoma from Sardinia,” The Journal of Infectious Diseases, vol. 177, no. 6, pp. 1715–1718, 1998.

[4] J. Iscovich, P. Boffetta, R. Winkelmann, P. Brennan, and E. Aztiz, “Classic Kaposi’s sarcoma in jews living in Israel, 1961–1989.” Acquired Immunodeficiency Syndrome, vol. 12, no. 15, pp. 2067–2072, 1998.

[5] G. Di Lorenzo, “Update on classic Kaposi sarcoma therapy: new look at an old disease,” Critical Reviews in Oncology/Hematology, vol. 68, no. 3, pp. 242–249, 2008.

[6] C. Lebbé, C. Legendre, and C. Francès, “Kaposi sarcoma in transplantation,” Transplantation Reviews, vol. 22, no. 4, pp. 252–261, 2008.

[7] Y. Chang, E. Cesarman, M. Pessin et al., “Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma,” Science, vol. 266, no. 5192, pp. 1865–1869, 1994.

[8] V. Beral, T. A. Peterman, R. L. Berkelman, and H. W. Jaffe, “Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection?” The Lancet, vol. 335, no. 8682, pp. 123–128, 1990.

[9] K. Ariyoshi, M. Schim Van Der Loeff, and P. Cook, “Kaposi’s sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8,” Journal of Human Virology, vol. 1, no. 3, pp. 193–199, 1998.

[10] E. E. Brown, D. Whitby, F. Vitale et al., “Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma,” Cancer, vol. 107, no. 9, pp. 2282–2290, 2006.

[11] L. A. Anderson, C. Lauria, N. Romano et al., “Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily,” Cancer Epidemiology Biomarkers & Prevention, vol. 17, no. 12, pp. 3435–3443, 2008.

[12] J. J. Goedert, F. Vitale, C. Lauria et al., “Risk factors for classical kaposi’s sarcoma,” CancerSpectrum Knowledge Environment, vol. 94, no. 22, pp. 1712–1718, 2002.

[13] H. Choi, “Epidemiology of crystal arthropathy,” Rheumatic Disease Clinics of North America, vol. 32, no. 2, pp. 255–273, 2006.

[14] E. Arrrowdee, C. J. Michet, C. S. Crowson, W. M. O’Fallon, and S. E. Gabriel, “Epidemiology of gout: is the incidence rising?” The Journal of Rheumatology, vol. 29, no. 11, pp. 2403–2406, 2002.

[15] K. Ichida, H. Matsuo, T. Takada et al., “Decreased extra-renal urate excretion is a common cause of hyperuricemia,” Nature Communications, vol. 3, no. 1, p. 764, 2012.

[16] J. G. Puig, R. J. Torres, E. de Miguel, A. Sánchez, R. Bailén, and J. R. Banegas, “Uric acid excretion in healthy subjects: a nomogram to assess the mechanisms underlying purine metabolic disorders,” Metabolism, vol. 61, no. 4, pp. 512–518, 2012.

[17] K. C. Lin, H. Y. Lin, and P. Chou, “Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen,” The Journal of Rheumatology, vol. 27, no. 4, pp. 1045–1050, 2000.

[18] Y. Zhu, B. J. Pandya, and H. K. Choi, “Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007–2008,” Arthritis & Rheumatism, vol. 63, no. 10, pp. 3136–3141, 2011.

[19] S. P. Juraschek, E. R. Miller III., and A. C. Gelber, “Body mass index, obesity, and prevalent gout in the United States in 1988–1994 and 2007–2010,” Arthritis Care & Research, vol. 65, no. 1, pp. 127–132, 2013.

[20] MEDCALC Statistical Software, https://www.medcalc.org/.

[21] S. A. R. Rezaee, C. Cunningham, A. J. Davison, and D. J. Blackbourn, “Kaposi’s sarcoma-associated herpesvirus immune modulation: an overview,” Journal of General Virology, vol. 87, no. 7, pp. 1781–1804, 2006.

[22] P. S. Moore, C. Boshoff, R. A. Weiss, and Y. Chang, “Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV,” Science, vol. 274, no. 5293, pp. 1739–1744, 1996.

[23] E. Caselli, M. Galvan, E. Cassai, A. Caruso, L. Sighinolfi, and D. Di Luca, “Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells,” Blood, vol. 106, no. 8, pp. 2790–2797, 2005.

[24] T. Kawai and S. Akira, “Innate immune recognition of viral infection,” Nature Immunology, vol. 7, no. 2, pp. 131–137, 2006.

[25] S. Akira, K. Takeda, and T. Kaisho, “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunology, vol. 2, no. 8, pp. 675–680, 2001.

[26] S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004.

[27] J. West and B. Damania, “Upregulation of the TLR3 pathway by Kaposi’s sarcoma-associated herpesvirus during primary infection,” Journal of Virology, vol. 82, no. 11, pp. 5440–5449, 2008.

[28] M. D. Turner, B. Nediжia, T. Hurst, and D. J. Pennington, “Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1843, no. 11, pp. 2563–2582, 2014.

[29] J. W. Griffith, C. L. Sokol, and A. D. Luster, “Chemokines and chemokine receptors: positioning cells for host defense and immunity,” Annual Review of Immunology, vol. 32, no. 1, pp. 659–702, 2014.

[30] Y. Toyoda, S. Tabata, J. Kishi et al., “Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synovocytes,” Arthritis & Rheumatology, vol. 66, no. 3, pp. 560–568, 2014.

[31] S. L. Wallace, H. Robinson, A. T. Masi, J. L. Decker, D. J. McCarty, and T. S.-F. Yu, “Preliminary criteria for the classification of the acute arthritis of primary gout,” Arthritis & Rheumatism, vol. 20, no. 3, pp. 895–900, 1977.

[32] T. O. Crișan, M. C. Cleophas, M. Oosting et al., “Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra,”
[33] T. O. Crișan, M. C. P. Clephas, B. Novakovic et al., “Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 21, pp. 5485–5490, 2017.

[34] E. Y. Lee, Z. H. Lee, and Y. W. Song, “The interaction between CXCL10 and cytokines in chronic inflammatory arthritis,” Autoimmunity Reviews, vol. 12, no. 5, pp. 554–557, 2013.

[35] N. Kerur, M. V. Veettil, N. Sharma-Walia et al., “IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection,” Cell Host & Microbe, vol. 9, no. 5, pp. 363–375, 2011.

[36] K. Schroder and J. Tschopp, “The inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010.

[37] S. R. Kingsbury, P. G. Conaghan, and M. F. McDermott, “The role of the NLRP3 inflammasome in gout,” Journal of Inflammation Research, vol. 4, pp. 39–49, 2011.